almagate has been researched along with Neovascularization, Optic Disc in 16 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 11 (68.75) | 29.6817 |
2010's | 5 (31.25) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
DeCastro Molina, JA; George, PP; Heng, BH | 1 |
Delle Noci, N; Iaculli, C; Prascina, F; Querques, G | 1 |
Aguilar, E; Banin, E; Bird, A; Dorrell, MI; Friedlander, M; Gariano, R; Gasmi, M; Heckenlively, J; Jacobson, R; Ramirez, GA; Siuzdak, G; Yanes, O | 1 |
Banda, RM; Giuliari, GP; González, VH; Guel, DA | 1 |
Thelen, U | 1 |
Agostini, HT; Bates, DO; Beazley Long, N; Bevan, HS; Churchill, AJ; Floege, J; Gammons, M; Harper, SJ; Hua, J; Lehrling, C; Magnussen, AL; Rennel, ES | 1 |
Dietzel, M; Gutfleisch, M; Heimes, B; Lommatzsch, A; Pauleikhoff, D; Spital, G | 1 |
Cortez, MA; Cortez, RT; Giuliari, GP; Guel, DA | 1 |
Moshfeghi, AA; Puliafito, CA | 1 |
Adamis, AP; Altaweel, M; Barrett, K; Bressler, NM; Cunningham, ET; Davis, MD; Goldbaum, M; Gonzales, C; Guyer, DR; Patel, M | 1 |
D'Amico, DJ; Vavvas, D | 1 |
Gillies, MC | 1 |
Goldbaum, M; Katz, B | 1 |
Bansal, AG; Majji, AB; Narayanan, R; Thomas, R | 1 |
Ulińska, M | 1 |
Pieramici, DJ; Rabena, MD | 1 |
6 review(s) available for almagate and Neovascularization, Optic Disc
Article | Year |
---|---|
The methodological quality of systematic reviews comparing intravitreal bevacizumab and alternates for neovascular age related macular degeneration: A systematic review of reviews.
Topics: Angiogenesis Inhibitors; Aptamers, Nucleotide; Bevacizumab; Humans; Intravitreal Injections; Macular Degeneration; Retinal Neovascularization; Vascular Endothelial Growth Factor A | 2014 |
Selective and pan-blockade agents in the anti-angiogenic treatment of proliferative diabetic retinopathy: a literature summary.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Humans; Macular Edema; Ranibizumab; Retinal Neovascularization; Vascular Endothelial Growth Factor A | 2010 |
Pegaptanib sodium for the treatment of neovascular age-related macular degeneration.
Topics: Aptamers, Nucleotide; Clinical Trials as Topic; Humans; Macular Degeneration; Retinal Neovascularization; Vascular Endothelial Growth Factor A; Vitreous Body | 2005 |
Pegaptanib (Macugen): treating neovascular age-related macular degeneration and current role in clinical practice.
Topics: Aptamers, Nucleotide; Humans; Macular Degeneration; Retinal Neovascularization; Treatment Outcome; Vascular Endothelial Growth Factor A | 2006 |
Macugen (pegaptanib sodium), a novel ocular therapeutic that targets vascular endothelial growth factor (VEGF).
Topics: Aptamers, Nucleotide; Humans; Macular Degeneration; Retinal Neovascularization; Treatment Outcome; Vascular Endothelial Growth Factor A | 2006 |
[Pegaptanib sodium in treatment of wet AMD].
Topics: Aptamers, Nucleotide; Humans; Macular Degeneration; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Retinal Neovascularization; Vascular Endothelial Growth Factor A | 2006 |
1 trial(s) available for almagate and Neovascularization, Optic Disc
Article | Year |
---|---|
Intravitreal injection of pegaptanib sodium for proliferative diabetic retinopathy.
Topics: Adult; Aged; Angiogenesis Inhibitors; Aptamers, Nucleotide; Diabetic Retinopathy; Female; Humans; Injections, Intralesional; Laser Coagulation; Male; Middle Aged; Pilot Projects; Prospective Studies; Retinal Neovascularization | 2009 |
9 other study(ies) available for almagate and Neovascularization, Optic Disc
Article | Year |
---|---|
Intravitreal pegaptanib sodium (Macugen) for radiation retinopathy following episcleral plaque radiotherapy.
Topics: Aptamers, Nucleotide; Brachytherapy; Choroid Neoplasms; Exudates and Transudates; Female; Fluorescein Angiography; Humans; Injections; Melanoma; Middle Aged; Optic Disk; Radiation Injuries; Retina; Retinal Hemorrhage; Retinal Neovascularization; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Vitreous Body | 2008 |
Antioxidant or neurotrophic factor treatment preserves function in a mouse model of neovascularization-associated oxidative stress.
Topics: Angiogenesis Inhibitors; Animals; Antioxidants; Aptamers, Nucleotide; Disease Models, Animal; Electroretinography; Gene Expression; Gene Expression Profiling; Gene Transfer Techniques; Lipid Peroxidation; Mice; Mice, Inbred C57BL; Mice, Knockout; Nerve Growth Factors; Opsins; Oxidative Stress; Receptors, LDL; Retina; Retinal Cone Photoreceptor Cells; Retinal Neovascularization; Retinal Pigment Epithelium; Retinal Rod Photoreceptor Cells; Retinitis Pigmentosa; Rhodopsin; Vascular Endothelial Growth Factor A | 2009 |
[Clinical experience with pegaptanib in the treatment of age-related macular degeneration (AMD)].
Topics: Aged; Aged, 80 and over; Aptamers, Nucleotide; Female; Fluorescein Angiography; Humans; Injections; Intraocular Pressure; Macular Degeneration; Male; Retinal Neovascularization; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2010 |
VEGF-A165b is cytoprotective and antiangiogenic in the retina.
Topics: Angiogenesis Inhibitors; Animals; Animals, Newborn; Aptamers, Nucleotide; Cell Movement; Cell Survival; Cells, Cultured; Cytoprotection; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Endothelium, Vascular; Epithelial Cells; Half-Life; Humans; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor Binding Proteins; Mice; Mice, Inbred C57BL; Rats; Recombinant Proteins; Retinal Neovascularization; Retinal Vessels; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
[Retinal angiomatous proliferation with associated pigment epithelium detachment: anti-VEGF therapy].
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Female; Fluorescein Angiography; Follow-Up Studies; Humans; Indocyanine Green; Intravitreal Injections; Macular Degeneration; Male; Ophthalmoscopes; Ranibizumab; Retina; Retinal Detachment; Retinal Neovascularization; Retrospective Studies; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Visual Acuity | 2011 |
Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals.
Topics: Adult; Aged; Aged, 80 and over; Aptamers, Nucleotide; Diabetic Retinopathy; Female; Fluorescein Angiography; Humans; Injections; Macular Edema; Male; Middle Aged; Randomized Controlled Trials as Topic; Retinal Neovascularization; Retrospective Studies; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2006 |
What we don't know about avastin might hurt us.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Humans; Ranibizumab; Retinal Neovascularization; Vascular Endothelial Growth Factor A | 2006 |
Neovascular changes after pegaptanib in diabetics.
Topics: Aptamers, Nucleotide; Diabetic Retinopathy; Humans; Randomized Controlled Trials as Topic; Retinal Neovascularization; Vascular Endothelial Growth Factor A | 2007 |
Anti-VEGF therapy: comparison of current and future agents.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Forecasting; Humans; Ranibizumab; Retinal Neovascularization; Vascular Endothelial Growth Factor A | 2008 |